Back to search
CD30-Positive Diffuse Large B-Cell Lymphoma
Clinical trial pipeline · Data from ClinicalTrials.gov
See which CD30-Positive Diffuse Large B-Cell Lymphoma trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which CD30-Positive Diffuse Large B-Cell Lymphoma trials you may qualify forThis study involves patients with diffuse large B cell lymphoma (DLBCL), natural killer/T-cell lymphoma (NKTL), or classical Hodgkin lymphoma (cHL) (referred to…
This first-in-human trial will assess the safety, feasibility, and efficacy of an immunotherapy with a novel CD30 antibody conjugated to a CD3 antibody that is…
Patients with CD30 positive DLBCL, primary refractory or in first relapse after R-CHOP or R-CHOP-like therapy will receive brentuximab vedotin in combination wi…
The antibody drug conjugate (ADC) brentuximab vedotin (BV), targeting CD30, is currently registered for the treatment of previously untreated stage III-IV Hodgk…
This is a phase 1 study to evaluate safety and dose-limiting toxicity of autologous CD30.CAR-T in subjects with relapsed or refractory CD30+ Non-Hodgkin Lymphom…
This is a Phase I/II multicenter single arm non-randomized open label study of the investigational drug, brentuximab vedotin, given in combination with routine…